首页 | 本学科首页   官方微博 | 高级检索  
     


Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma
Affiliation:1. Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany;2. Foundation Medicine, Inc., Cambridge, MA, USA;3. Institute of Molecular Medicine and Cell Research, ZBMZ, Faculty of Medicine, University of Freiburg, 79104, Freiburg, Germany;4. German Cancer Consortium (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany;5. Comprehensive Cancer Center Freiburg (CCCF), Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, 79106, Freiburg, Germany;6. Center for Biological Signalling Studies BIOSS, University of Freiburg, 79104, Freiburg, Germany;7. Translational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy;1. West Cancer Center, Medical Director, Germantown, Tennessee;2. Foundation Medicine, Clinical Development, Cambridge, Massachusetts;3. Flatiron Health, Medical Director, New York, New York;4. Genentech, Inc., Oncology Biomarker Development & Medical Affairs, South San Francisco, California;5. Foundation Medicine, Clinical Operations, Cambridge, Massachusetts;6. Foundation Medicine, Cancer Genomics Research, Cambridge, Massachusetts;7. Foundation Medicine, Decision Sciences, Cambridge, Massachusetts;8. Tennessee Oncology, Medical Oncology, Chattanooga, Tennessee;1. Service d’Hépato-Gastroentérologie, Cliniques universitaires Saint-Luc, UCLouvain, 1200 Brussels, Belgium;2. Service d’Endocrinologie, Diabétologie et Nutrition, Cliniques universitaires Saint-Luc, UCLouvain, 1200 Brussels, Belgium;3. Laboratory of Gastroenterology and Hepatology, Institut de Recherche Expérimentale et Clinique, UCLouvain, 1200 Brussels, Belgium;1. National Center for Liver Cancer, the Third Affiliated Hospital of Naval Medical University, Shanghai, China;2. International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, the Naval Medical University, Shanghai, China;3. The First Affiliated Hospital of Naval Medical University, Shanghai, China;4. Department of Oncology, Eastern Hepatobiliary Surgery Hospital, the Naval Military Medical University, Shanghai, China;5. Department of Surgery, Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, Shanghai, China;6. Children’s Hospital of Soochow University, Suzhou, P. R. China;7. Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer, the Naval Medical University and Ministry of Education, Shanghai, China;8. State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China;9. Shanghai Key Laboratory of Hepato-biliary Tumor Biology, Shanghai, China;1. Nordic Bioscience, Denmark;2. Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom;3. Newcastle NIHR Biomedical Research Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom;4. Astrazeneca, Regulatory Affairs, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, Gothenburg, Sweden;5. Roche Diagnostics International, Rotkreuz, Switzerland;6. Gilead Sciences, Inc, Foster City, California, USA;7. Novartis, East Hanover, NJ 07936, USA;8. Takeda Development Center Americas, Inc., 95 Hayden Avenue, Lexington, MA 02421, USA;9. Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom;10. Institute of Translational Immunology and Research Center for Immune Therapy, Mainz University Medical Center, 55131, Mainz, Germany;11. Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA;12. Centre for Digestive Diseases, Lausanne, Switzerland;13. Perspectum, Oxford, OX4 2LL, United Kingdom;14. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany;15. Sorbonne University, Paris, France;16. Pitié-Salpêtrière Hospital, Paris, France;17. Global Product Development, Internal Medicine and Hospital, Pfizer Inc, Florida, USA;18. Department of Epidemiology and Data Science, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, the Netherlands;1. Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong;2. Medical Data Analytics Centre (MDAC), The Chinese University of Hong Kong, Hong Kong;3. Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong;4. Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong;5. Department of Internal Medicine, Union Hospital, Hong Kong;1. College of Life Sciences, Hubei Key Laboratory of Cell Homeostasis, Department of Oncology of Renmin Hospital, Wuhan University, Wuhan 430072, China;2. CAS Key Laboratory of Plant Germplasm Enhancement and Specialty Agriculture, Wuhan Botanical Garden, Chinese Academy of Sciences, Wuhan 430074, China;3. University of Chinese Academy of Sciences, Beijing 100049, China;4. Department of Hepatobiliary and Pancreatic Surgery, Hubei Cancer Hospital, Wuhan 430079, China;5. Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430060, China;6. Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China;7. Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China;8. Institute of Model Animal of Wuhan University, Wuhan 430071, China;9. School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China
Abstract:
><ol class=
  • Download : Download high-res image (297KB)
  • Download : Download full-size image
  • Keywords:biliary tract cancer  precision medicine  targeted therapy  immunotherapy  genomic alterations
    本文献已被 ScienceDirect 等数据库收录!
    设为首页 | 免责声明 | 关于勤云 | 加入收藏

    Copyright©北京勤云科技发展有限公司  京ICP备09084417号